Novartis AG NVS

Mr. Harry Kirsch, Chief Financial Officer Pharmaceuticals Division, Novartis Pharma AG, Switzerland (2010-2013); Chief Financial Officer of Pharma Europe, Novartis Pharma AG, Switzerland (2008-2010); Head of Business Planning & Analysis for the Pharmaceuticals Division, Novartis Pharma AG, Switzerland (2005-2008); Head Finance Global Primary Care, Novartis Pharma AG, Switzerland (2003-2005); Finance positions at Procter & Gamble (1991-2003). Past: Represented Novartis on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd. (2015-2018). Education- Diploma degree in industrial engineering and economics (Diplom-Wirtschaftsingenieur), University of Karlsruhe, Germany.

Mr. Victor Bulto, President, US, President, Novartis Pharmaceuticals Corporation, US (2019-2022); Vice President & Head Immunology & Dermatology Franchise, Novartis US (2017-2019); Vice President & Head US Alcon Pharmaceuticals, US (2016-2017); Head Neuroscience Franchise, Region Europe, Novartis, Switzerland (2013-2016); Business Franchise Head Neuroscience, Novartis, Spain (2012-2013); Business Franchise Head Neuroscience/MS, Respiratory, Osteoarticular, Spain, Novartis (2010-2012); Marketing Head Respiratory, Osteoarticular, Novartis, Spain (2009-2010). Current: Board member, Labcorp, US; Board member, Biotechnology Innovation Organization (BIO), US; Board member, Advisory Board of the Leonard D. Schaeffer Center for Health Policy & Economics, US; Education- Master of business administration, ESADE Business School, Spain; Master's degree in health economics and pharmacoeconomics, Pompeu Fabra University Spain; Master's degree in chemical engineering, Ramon Llull University, Spain; Bachelor's degree in chemistry, Ramon Llull University, Spain.

Mr. Patrick Horber, Senior vice president, AbbVie, president Immunology, AbbVie, US (July 2023-September 2023); President, US commercial operations, Immunology, AbbVie, US (2020-2023); Vice president and head of global marketing and commercial operations, AbbVie, US (2019-2020); Vice president and managing director, AbbVie, Germany (2015-2019); Managing director, AbbVie, Switzerland (2013-2015); Managing director, Abbott, Switzerland (2012-2012); Leadership roles at headquarters and country operations, Roche (2005-2012). Current: Board member and vice-chair of the patient access committee, European Federation of Pharmaceutical Industries and Associations (EFPIA); Board member, economiesuisse; Past: Board member and chair of the strategy and politics committee, Verband Forschender Arzneimittelhersteller, Germany (2016-2019); Interpharma, the association of Switzerland's research-based pharmaceutical industry; - Chair of the executive committee (2015-2015); - Member of the president's bureau (2015-2015); - Member of the executive committee and the board (2013-2015)?; Education- Doctor of medicine (M.D.), University of Zurich, Switzerland.

Giovanni Caforio has had an international career in the healthcare industry spanning more than 35 years. He graduated in medicine and surgery in Italy in 1988, and has held senior leadership positions at Abbott Laboratories and Bristol Myers Squibb (BMS) in several European countries and the US. He was CEO of BMS from 2015 to 2023 and Chair of the company's board of directors from 2017 to 2024. Under his leadership, BMS nearly tripled its revenue, undertook several strategic acquisitions and partnerships, and launched 12 new medicines. Giovanni Caforio currently serves on the board of Stryker Corp. He is fluent in Italian, French, Spanish, Portuguese and English. Board chair, BMS, US (2017-2024); Chief Executive Officer, BMS, US (2015-2023); Chief Operating Officer, BMS, US (2014-2015); Executive Vice President, Chief Commercial Officer, BMS, US (2013-2014); President, US Pharmaceuticals, BMS, US (2011-2013); Various managerial positions at BMS and Abbot Laboratories in the US, France, Italy, Portugal and Spain (1990-2011). Board member and chair of the compensation and human capital committee, Stryker Corp, US. Past- Board chair, PhRMA (2019-2020), US. Education- Doctor of medicine and surgery, Sapienza University, Rome, Italy.

As co-founder and CEO of MorphoSys AG, Simon Moroney played a central role in establishing the company as a force in the field of therapeutic antibodies, with one of the broadest pipelines of drug candidates in the industry. Mr. Moroney holds both a doctorate and a Master's degree in chemistry. Co-founder and CEO, MorphoSys AG, Germany (1992-2019); Research associate, Department of Pharmacology, University of Cambridge, UK (1991-1992); Assistant professor, Department of Chemistry, University of British Columbia, Canada (1989-1990). Current: Board chair and chair of the remuneration and nomination committee, Biotalys NV, Belgium. Education- Doctorate in chemistry, University of Oxford, UK. Master's degree in chemistry, University of Waikato, New Zealand.

A scientist by training, John D. Young has over 35 years of experience in the healthcare industry and brings a wealth of experience in leadership, strategy, business development and commercialization of innovative medicines to the Novartis Board of Directors. He joined Pfizer in 1987 as a sales representative and held positions of increasing seniority across the company, including as a member of Pfizer's executive leadership team for a decade. As Pfizer's group president and chief business officer from 2019 until 2022, Mr. Young also played an integral role in the development and delivery of the Pfizer-BioNTech COVID-19 vaccine. Senior advisor to the CEO, Pfizer, US (2022); Group president and chief business officer, Pfizer, US (2019-2022); Group president, innovative health business, Pfizer, US (2018); Group president, essential health business, Pfizer, US (2014-2017); President and general manager, global primary care business unit, Pfizer, US (2012-2013); Regional president, primary care business unit for Europe and Canada, Pfizer, UK (2009-2012); Various managerial positions, Pfizer, UK and Australia (1987-2008). Current: Board member, Johnson Controls International, Ireland. Past: Board member and chair of the compensation committee, Arvinas Inc, US (2022-2025); Board member, Imbria Pharmaceuticals, US (2022-2024); Board member, Haleon, UK (2022-2023); Board member, GSK Consumer Health Joint Venture, UK (2019-2022); Board member, Biotechnology Innovation Organization (BIO), US (2018-2021); US bio-pharmaceutical representative, UK Government Life Sciences Council, UK (2007-2021); Board member, National Committee for US China Relations, US (2014-2017); Board member, European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium (2012-2017); Education- Master of business administration, University of Strathclyde, UK; Bachelor's degree in biological sciences, University of Glasgow, UK.

Frans van Houten is passionate about purpose-driven innovation, entrepreneurship and business transformation to drive customer value and competitiveness. Under his leadership as CEO of Royal Philips, the company transformed into a leading health technology solutions company, leveraging data and informatics to improve healthcare provider results, and became a forerunner across ESG dimensions, having become carbon neutral in its operations since 2020 and recycling over 90% of its waste. Mr. van Houten was an initiator of the World Economic Forum Compact for Responsive and Responsible Leadership as well as founder and co-chair of the Platform to Accelerate the Circular Economy. CEO and chair of the executive committee and the board of management, Royal Philips NV, Netherlands (2011-2022); Interim management, ING Group NV, Netherlands (2009-2010); CEO and chair of the management board, NXP Semiconductors NV (formerly Philips Semiconductors NV), Netherlands (2004-2009); Various managerial positions at Royal Philips Electronics NV, Netherlands (1986-2004). Current: Board chair and chair of the nominating and corporate governance committee, Absci Corporation, US; Board chair, Castor EDC, Netherlands; Board member, Affidea Group, Netherlands; Board chair, Synthesis Health Inc, Canada; Past: Member of the steering committee, European Round Table for Industry (ERT), Belgium (2014-2022); Vice chair and member of the supervisory board, Philips Lighting, Netherlands (2016-2017); Education- Master's degree in economics and business management, Erasmus University Rotterdam, Netherlands; Bachelor's degree in economics, Erasmus University Rotterdam, Netherlands.

Patrice Bula has 40 years of global management experience and is a leader in the consumer goods industry across established and emerging markets. He has served in various senior roles at Nestle SA, including as general manager of its businesses in China, Germany and South Africa. Most recently, he successfully led the Nestle Group's brand strategies, digital marketing transformation and Nespresso business. Executive vice president and head of strategic business units, marketing, sales and Nespresso, Nestle SA, Switzerland (2011-2021); Market head of the Greater China region, Nestle SA, Switzerland (2007-2011); Market head of Germany, Nestle SA, Switzerland (2003-2007); Head of the confectionery and biscuits strategic business unit, Nestle SA, Switzerland (2000-2003); Various managerial positions at Nestle SA, Switzerland (1980-2000). Current: Board member and vice chair, Schindler AG, Switzerland; Board chair, European Pizza Group Topco Sarl, Luxembourg; Board chair, Froneri Lux Topco Sarl, Luxembourg; Board member and chair of the ESG committee, New Tiger LLC, US; Past:; Board co-chair (2020-2021) and member (2015-2021), Cereal Partners Worldwide SA, Switzerland (Nestle representative); Board member, Froneri Lux Topco Sarl, Luxembourg (Nestle representative) (2016-2020); Board member, Bobst Group SA, Switzerland (2017-2019); Board chair, Blue Bottle Coffee Inc., US (Nestle representative) (2017-2019); Board chair, Nestle Nespresso SA, Switzerland (Nestle representative) (2011-2019); Board member, Hsu Fu Chi Food Companies, China (Nestle representative) (2011-2019). Education- Program for executive development, IMD Business School, Switzerland; Master's degree in economic sciences, HEC Lausanne, Switzerland.

Daniel Hochstrasser is an independent dispute resolution specialist practicing in Zurich, Switzerland. He led Bar & Karrer, one of the leading Swiss law firms, from 2011 to 2021 as CEO/Senior Partner. In addition, he was the head of the firm's dispute resolution practice for 15 years. He frequently represented parties in complex disputes arising from matters such as M&A transactions, industrial and infrastructure projects, and license, distribution and development agreements, particularly in the pharmaceutical industry. He has published extensively on arbitration and litigation, and lectures at the University of Zurich and the University of St. Gallen in Switzerland. Attorney-at-law, Daniel Hochstrasser AG, Switzerland (since 2023); Attorney-at-law and partner, Bar & Karrer AG, Switzerland (1993-2022); Senior partner and Board chair, Bar & Karrer AG, Switzerland (2011-2021); Lawyer, District Court of Affoltern, Court of Appeals/Court of Cassation of Zurich, Switzerland (1987-1992); In-house lawyer, Staubli SA, France (1986-1987). Current: Board chair, Daniel Hochstrasser AG, Switzerland; Vice president, ICC Court of Arbitration, France; Member of the Ethics Court, Zurich Bar Association, Switzerland; Past: Board member, Finland Arbitration Institute, Finland (2019-2025); Board chair, Bar & Karrer AG, Switzerland (2011-2021); Member, ICC Court of Arbitration, France (2015-2021); Member of the Court, Swiss Arbitration Chambers, Switzerland (2004-2014); Education- Master of laws (LL.M.), Cornell Law School, US; Bar examination, Switzerland; Licentiatus iuris, University of Zurich, Switzerland.

Nancy C. Andrews has extensive experience as a physician, scientist, professor and senior administrator at leading academic institutions and hospitals. Her distinguished career spans more than 30 years, with leadership roles at Harvard Medical School, Duke University School of Medicine and Boston Children's Hospital. Since 2023, Dr. Andrews is credited with conducting research that led to advances in understanding iron biology and iron diseases. Professor in residence of pediatrics, Harvard Medical School, US (since 2023); Executive vice president and chief scientific officer, Boston Children's Hospital, US (since 2021); Dean emerita, Duke University School of Medicine, and vice chancellor emerita for academic affairs, Duke University, US (since 2017); Dean, Duke University School of Medicine, and vice chancellor for academic affairs, Duke University, US (2007-2017); Professor of pediatrics, pharmacology and cancer biology, Duke University, US (2007-2021); Dean for basic sciences and graduate studies, Harvard Medical School, US (2003-2007); Director, Harvard/MIT M.D.-Ph.D. Program, US (1999-2003); Biomedical research investigator, Howard Hughes Medical Institute, US (1993-2006). Current: Board member and chair of the governance and nominating committee, Charles River Laboratories International Inc., US; Board member, Maze Therapeutics Inc., US; Home secretary (since July 2023) and council member, National Academy of Sciences, US. Past: Chair, American Academy of Arts and Sciences, US (2017-2023); Member of the executive committee of the corporation, Massachusetts Institute of Technology, US (2019-2022); Council member, National Academy of Medicine, US (2013-2019); Member of the scientific management review board, National Institutes of Health, US (2014-2019); Chair, Burroughs Wellcome Fund, US (2011-2019); Education- Doctor of medicine, Harvard Medical School, US; Doctorate in biology, Massachusetts Institute of Technology, US; Master's and bachelor's degrees in molecular biophysics and biochemistry, Yale University, US.

Elizabeth McNally is a human geneticist and cardiologist with extensive experience as a physician, scientist, professor and senior administrator at leading academic institutions in the US. She qualified as a medical doctor at the Albert Einstein College of Medicine in New York City. Elizabeth McNally is a practicing cardiologist with expertise in cardiovascular genetics, with postgraduate training at the Brigham and Women's Hospital in Boston. With interests in the genetics of cardiovascular and neuromuscular disorders, she has had research and leadership roles at the University of Chicago and Northwestern University. She is the founder, CEO and a board member of Ikaika Therapeutics. Editor-in-chief, Journal of Clinical Investigation (since 2022); Director, Center for Genetic Medicine, and professor of genetic medicine, Department of Medicine, Northwestern University, Chicago, IL, US (since 2014); Professor, Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, US (since 2014); Professor, University of Chicago, Chicago, IL, US (2006-2014); Director, Institute for Cardiovascular Research, University of Chicago, Chicago, IL, US (2005-2014); Associate professor, University of Chicago, Chicago, IL, US (2003-2006); Assistant professor, University of Chicago, Chicago, IL, US (1996-2003); Clinical and research fellow in medicine, Harvard Medical School, Boston, MA, US (1990-1996). Current: Board member, Ikaika Therapeutics, US; Board member, Muscular Dystrophy Association of America, US. Education- Doctor of medicine, Albert Einstein College of Medicine, US; Doctorate in microbiology and immunology, Albert Einstein College of Medicine, US; Bachelor's degree in biology and philosophy, Columbia University, US.

Ms. Karen L. Hale, Chief Legal Officer of Novartis since May 15, 2021. Professional experience: Vice president, deputy general counsel, AbbVie Inc., US (2019-2021); Vice president, chief ethics and compliance officer, AbbVie Inc., US (2013-2019); Vice president, litigation and legal specialty operations, AbbVie Inc., US (2013); Divisional vice president, commercial litigation, Abbott Laboratories, US (2006-2012); Began practicing law in 1994 and joined Abbott in 1997. Education: Bar memberships: Illinois and Virginia, US; Juris doctor, William & Mary Law School, US; Bachelor's degree in economics, Duke University, US.

Mr. Aharon Gal, PhD, Senior analyst, US biopharmaceutical, Sanford Bernstein, US (2020-2022); Senior analyst, US specialty pharmaceuticals and Biotech, Sanford Bernstein, US (2016-2020); Senior analyst, US specialty pharmaceuticals and EU mid-cap pharmaceuticals, Sanford Bernstein, US, UK (2013-2016); Senior analyst, US specialty pharmaceuticals, Sanford Bernstein, US (2004-2013); Vice president, Canon US Life Sciences, US (2003-2004); Consultant, team leader, manager, The Boston Consulting Group, Inc., US, Singapore, China (1996-2002). Education- Ph.D. in biochemistry, Massachusetts Institute of Technology, US and B.Sc. in chemistry, Emory University, US

Mr. Robert Kowalski, Executive Vice President and Global Head of Regulatory Affairs (2018-2021), and US Head of Global Drug Development (2009-2015 and 2017-2021), Novartis Pharmaceuticals Corporation, US; Ad interim President, Novartis Corporation, US (2021); Ad interim Head of Global Drug Development and Chief Medical Officer, Novartis AG, Switzerland (2018); Senior Vice President and Head of Regulatory Affairs, Novartis Pharmaceuticals Corporation, US (2009-2015 and 2017-2018); Senior Vice President and Head of Regulatory Affairs, Novartis Pharma AG, Switzerland (2015-2017); Global Head of Country Medical Development, Novartis Pharmaceuticals Corporation, US (2010-2011); Previously held regulatory leadership roles at Schering-Plough Corporation (now Merck) and Pharmacia Corporation (now Pfizer). Past: Advisory board member, Industry Pharmacists Organization, US (2015-2024). Education- Doctor of pharmacy, University of Wisconsin-Madison, US and Bachelor's degree in pharmaceutical sciences, University of Wisconsin-Madison, US.

Mr. Stefen Lang, PhD, Global Head of Novartis Technical Operations (2017-2022); Global Head of Biologics Technical Development and Manufacturing, Novartis Technical Operations, Switzerland (2015-2017); Global Head of Technical Research and Development, Novartis Pharmaceuticals, Switzerland (2009-2015); Joined Novartis in 1994 as Head of Laboratory in Research, and over the years held positions of increasing responsibility within Pharmaceuticals Development. Current: Board member, Bachem Holding AG, Switzerland. Education- Doctorate in pharmaceutical technology, Swiss Federal Institute of Technology, Switzerland; Master's degree in pharmaceutical sciences, University of Heidelberg, Germany.

Ms. Fiona Marshall, PhD, Senior vice president, head of discovery, preclinical and translational medicine, Merck & Co., US, (2021-2022); Vice president, global head of neuroscience, Merck & Co., US (2019-2021); Vice president, head of UK discovery research, Merck & Co., UK (2018-2019); Executive vice president and chief scientific officer, Sosei Heptares, UK (2015-2018); Chief scientific officer and founder, Heptares Therapeutics, UK (2006-2018). Education- Doctorate in neuroscience, University of Cambridge, UK. Bachelor's degree in biochemistry, University of Bath, UK.

Dr. Shreeram Aradhye, M.D., Executive vice president & chief medical officer, Dicerna Pharmaceuticals, US (2020-2022); Executive vice president & chief development officer, Axcella Health, US (2019-2020); Global Head, Medical Affairs and Chief Medical Officer, Pharmaceuticals, Novartis, US & Switzerland (2017-2019); Global Head, Development Franchise, Neuroscience, and US Head, Development, Novartis, US & Switzerland (2013-2017); Executive Global Program Head, Multiple Sclerosis, Novartis, Switzerland (2012-2013); Head, Global Development India, Novartis, India (2011-2012); Head, Global Clinical Development & Medical Affairs, Biosimilars, Sandoz, Germany (2009-2011); Positions of increasing responsibility at Novartis (1999-2009); Education; Chief resident and teaching fellow in internal medicine, Newton Wellesley Hospital, US; Resident in internal medicine, Newton Wellesley Hospital, US; Fellow in nephrology, St Luke's Roosevelt Medical Center, US; Resident in internal medicine (M.D.), All India Institute of Medical Sciences, India; Bachelor of medicine and bachelor of surgery, All India Institute of Medical Sciences, India.